For prostate adenocarcinoma, findings from an early immunohistochemistry study by Ricote et al. [61] were successively confirmed and extended by our group; we reported the pro-metastatic role of IL-1β derived from human prostate cancer cells and the effects of blocking IL-1β signaling on the metastatic progression in pre-clinical animal models [62,63]. Here, IL1B is linked to prostate carcinoma.